Predicting response to neoadjuvant therapy in esophageal cancer

References

• Rice TW, Rusch VW, Apperson-Hansen C et al. Worldwide esophageal cancer collaboration. Dis. Esophagus.22, 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Lerut T, Moons J, Coosemans W et al. Multidisciplinary treatment of advanced cancer of the esophagus and gastroesophageal junction: a European center’s approach. Surg. Oncol. Clin. N. Am.17, 485–502 (2008).
   PubMed Web of Science ®Google Scholar
• Bhansali MS, Vaidya JS, Bhatt RG et al. Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies. Ann. Oncol.7, 355–359 (1996).
   PubMed Web of Science ®Google Scholar
• Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg.183, 274–279 (2002).
   PubMed Web of Science ®Google Scholar
• Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg.185, 538–543 (2003).
   PubMed Web of Science ®Google Scholar
• Kaklamanos IG, Walker GR, Ferry K et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann. Surg. Oncol.10, 754–761 (2003).
   PubMed Web of Science ®Google Scholar
• Malthaner R, Wong R, Rumble R et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med.2, 35 (2004).
   PubMed Web of Science ®Google Scholar
• Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Gut53, 925–930 (2004).
   PubMed Web of Science ®Google Scholar
• Greer S, Goodney P, Sutton J et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery137, 172–177 (2005).
   PubMed Web of Science ®Google Scholar
• Vogt K, Fenlon D, Rhodes S, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst. Rev.3, CD001556 (2006).
   Google Scholar
• Gebski V, Burmeister B, Smithers BM et al. Australian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol.8, 226–234 (2007).
   PubMed Web of Science ®Google Scholar
• Jin HL, Zhu H, Ling TS et al. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J. Gastroenterol.15, 5983–5991 (2009).
   PubMed Web of Science ®Google Scholar
• Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer73, 2680–2686 (1994).
   PubMed Web of Science ®Google Scholar
• Schneider PM, Baldus SE, Metzger R et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann. Surg.242, 684–692 (2005).
   PubMed Web of Science ®Google Scholar
• Schneider PM, Metzger R, Schaefer H et al. Response-evaluation by endoscopy, re-biopsy, and endoscopic ultrasound does not accurately predict histopathologic regression following neoadjuvant chemoradiation for esophageal cancer. Ann. Surg.248, 902–908 (2008).
   PubMed Web of Science ®Google Scholar
• Levine EA, Farmer MR, Clark P et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann. Surg.243, 472–478 (2006).
   PubMed Web of Science ®Google Scholar
• Gillham CM, Lucey JA, Keogan M et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br. J. Cancer95, 1174–1179 (2006).
   PubMed Web of Science ®Google Scholar
• Lordick F, Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol.8, 797–805 (2007).
   PubMed Web of Science ®Google Scholar
• Vallböhmer D, Hölscher AH, Dietlein M et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann. Surg.250, 888–894 (2009).
   PubMed Web of Science ®Google Scholar
• van Heijl M, Omloo JM, van Berge Henegouwen MI et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann. Surg.253, 56–63 (2011).
   PubMed Web of Science ®Google Scholar
• Vallböhmer D, Brabender J, Metzger R, Hölscher AH. Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J. Gastrointest. Surg.14(Suppl. 1), S75–S80 (2010).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Rice TW, Boyce GA et al. Adenocarcinoma of the esophagus and gastroesophageal junction. Clinical and pathologic assessment of response to induction chemotherapy. Am. J. Clin. Oncol.17, 14–18 (1994).
   PubMed Web of Science ®Google Scholar
• Brown WA, Thomas J, Gotley D et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br. J. Surg.91, 199–204 (2004).
   PubMed Web of Science ®Google Scholar
• Bates BA, Detterbeck FC, Bernard SA et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J. Clin. Oncol.14, 156–163 (1996).
   PubMed Web of Science ®Google Scholar
• Kalaitzakis E, Meenan J. Controversies in the use of endoscopic ultrasound in esophageal cancer staging. Scand. J. Gastroenterol.44, 133–144 (2009).
   PubMed Web of Science ®Google Scholar
• Jones DR, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer10, 26–32 (1999).
   Google Scholar
• Beer AJ, Wieder HA, Lordick F et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology239, 472–480 (2006).
   PubMed Web of Science ®Google Scholar
• Lordick F, Ruers T, Aust DE et al. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur. J. Cancer44, 1807–1819 (2008).
   PubMed Web of Science ®Google Scholar
• Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur. J. Cardiothorac. Surg.21, 657–663 (2002).
   PubMed Web of Science ®Google Scholar
• Shimada H, Hoshino T, Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br. J. Cancer86, 552–557 (2002).
   PubMed Web of Science ®Google Scholar
• Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J. Thorac. Cardiovasc. Surg.127, 1579–1586 (2004).
   PubMed Web of Science ®Google Scholar
• Xi H, Baldus SE, Warnecke-Eberz U et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin. Cancer Res.11, 8341–8347 (2005).
   PubMed Web of Science ®Google Scholar
• Sohda M, Ishikawa H, Masuda N et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int. J. Cancer110, 838–844 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist9(Suppl. 1), 2–10 (2004).
   PubMed Web of Science ®Google Scholar
• Shah MA, Jhawer M, Ilson DH et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J. Clin. Oncol.29, 868–874 (2011).
   PubMed Web of Science ®Google Scholar
• Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer95, 92–95 (2001).
   PubMed Web of Science ®Google Scholar
• Grimminger P, Vallböhmer D, Hoffmann A et al. Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. J. Surg. Oncol.100, 447–451 (2009).
   PubMed Web of Science ®Google Scholar
• Nakashima S, Natsugoe S, Matsumoto M et al. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res.20, 1933–1937 (2000).
   PubMed Web of Science ®Google Scholar
• Heeren PA, Kloppenberg FW, Hollema H, Mulder NH, Nap RE, Plukker JT. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res.24, 2579–2583 (2004).
   PubMed Web of Science ®Google Scholar
• Warnecke-Eberz U, Metzger R, Miyazono F et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer Clin. Cancer Res.10, 3794–3799 (2004).
   PubMed Web of Science ®Google Scholar
• Kim MK, Cho KJ, Kwon GY et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur. J. Cancer44, 54–60 (2008).
   PubMed Web of Science ®Google Scholar
• Wu X, Gu J, Wu TT et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J. Clin. Oncol.24, 3789–3798 (2006).
   PubMed Web of Science ®Google Scholar
• Warnecke-Eberz U, Vallböhmer D, Alakus H et al.ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J. Gastrointest. Surg.13, 1411–1421 (2009).
   PubMed Web of Science ®Google Scholar
• Brabender J, Vallböhmer D, Grimminger P et al. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J. Gastrointest. Surg.12, 1815–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys.57, 1323–1327 (2003).
   PubMed Web of Science ®Google Scholar
• Miyazono F, Metzger R, Warnecke-Eberz U et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br. J. Cancer91, 666–672 (2004).
   PubMed Web of Science ®Google Scholar
• Shimada Y, Watanabe G, Yamasaki S et al. Histological response of cisplatin predicts patients’ survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur. J. Cancer36, 987–993 (2000).
   PubMed Web of Science ®Google Scholar
• Kitamura K, Saeki H, Kawaguchi H et al. Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology47, 419–423 (2000).
   PubMedGoogle Scholar
• Yamasaki M, Miyata H, Fujiwara Y et al.p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann. Surg. Oncol.17, 634–642 (2010).
   PubMed Web of Science ®Google Scholar
• Sarbia M, Ott N, Puhringer-Oppermann F et al. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br. J. Cancer97, 1404–1408 (2007).
   PubMed Web of Science ®Google Scholar
• Fareed KR, Al-Attar A, Soomro IN et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br. J. Cancer102, 1600–1607 (2010).
   PubMed Web of Science ®Google Scholar
• Langer R, Specht K, Becker K et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin. Cancer Res.11, 7462–7469 (2005).
   PubMed Web of Science ®Google Scholar
• Langer R, Ott K, Feith M et al. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J. Surg. Oncol.102, 503–508 (2010).
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol.5, 588–599 (2008).
   PubMedGoogle Scholar
• Luthra R, Wu TT, Izzo J et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J. Clin. Oncol.24, 259–267 (2006).
   PubMed Web of Science ®Google Scholar
• Kelly R, Appleyard V, Murray K et al. Detection of esophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br. J. Cancer103, 232–238 (2010).
   PubMed Web of Science ®Google Scholar